Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Stocks in this Quantisnow insightHealth Care
Historical context for ZYME
Across the 29 sessions after earlier ZYME headlines, the stock closed higher 18 times and lower 10 times, with a median move of 1.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ZYME | SPY |
|---|---|---|---|
| Oct 26, 2026 | Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 | +0.5% | +0.7% |
| Oct 23, 2026 | Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 | -0.8% | -0.5% |
| Oct 19, 2026 | Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma | +2.0% | +0.4% |
| Oct 15, 2026 | Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results | +4.0% | +0.3% |
| Sep 29, 2026 | TD Cowen initiated coverage on Zymeworks with a new price target | +0.3% | -0.2% |
| Sep 28, 2026 | Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition | +2.3% | -0.7% |
Quantisnow market dataNASDAQ
ZYME
Zymeworks Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for ZYME
Full ZYME profile on Quantisnow Follow ZYME and get a push notification the moment its next story breaks.